Literature DB >> 167667

Flavoxate, a potent phosphodiesterase inhibitor.

M Conti, I Setnikar.   

Abstract

The c-AMP phosphodiesterase inhibiting properties of flavoxate and of its main metabolite i.e. 3-methylflavone-8-carboxylic acid (MFCA), were assayed in vitro and compared to those of theophylline. Flavoxate and MFCA are competitive phosphodiesterase inhibitors, and are 21 and respectively 5 times more potent than theophylline. The smooth muscle relaxing activity of flavoxate possibly relies on this enzymatic mechanism.

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 167667

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN： 0003-9780


  4 in total

Review 1.  Flavoxate in urogynecology: an old drug revisited.

Authors:  Murat Zor; Emin Aydur; Roger Roman Dmochowski
Journal:  Int Urogynecol J       Date:  2014-12-06       Impact factor: 2.894

2.  Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. II. Effect of various PDE inhibitors on smooth muscle tone and cyclic nucleotide levels in vitro.

Authors:  M C Truss; S Uckert; C G Stief; W G Forssmann; U Jonas
Journal:  Urol Res       Date:  1996

Review 3.  Flavone acetic acid (LM 975, NSC 347512). A novel antitumor agent.

Authors:  P J O'Dwyer; D Shoemaker; D S Zaharko; C Grieshaber; J Plowman; T Corbett; F Valeriote; S A King; J Cradock; D F Hoth
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Effects of flavoxate hydrochloride on voltage-dependent Ba2+ currents in human detrusor myocytes at different experimental temperatures.

Authors:  Toshihisa Tomoda; Hai-Lei Zhu; Kazuomi Iwasa; Manami Aishima; Atsushi Shibata; Narihito Seki; Seiji Naito; Noriyoshi Teramoto
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-10-02       Impact factor: 3.000
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.